JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

3.69 5.73

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.4

Max

3.71

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+12.36% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-578M

543M

Vorige openingsprijs

-2.04

Vorige sluitingsprijs

3.69

Nieuwssentiment

By Acuity

50%

50%

186 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 apr 2026, 23:08 UTC

Winsten

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 23:07 UTC

Winsten

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:20 UTC

Winsten

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 apr 2026, 23:47 UTC

Marktinformatie

Global Equities Roundup: Market Talk

30 apr 2026, 23:47 UTC

Marktinformatie

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 apr 2026, 23:27 UTC

Marktinformatie

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 apr 2026, 23:22 UTC

Winsten

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 apr 2026, 23:20 UTC

Marktinformatie

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 apr 2026, 22:52 UTC

Winsten

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:33 UTC

Winsten

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 apr 2026, 22:32 UTC

Winsten

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 apr 2026, 22:32 UTC

Winsten

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 apr 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 apr 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 apr 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 apr 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 apr 2026, 22:11 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

30 apr 2026, 22:11 UTC

Marktinformatie

Global Equities Roundup: Market Talk

30 apr 2026, 22:11 UTC

Marktinformatie

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 apr 2026, 22:05 UTC

Winsten

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 21:57 UTC

Winsten

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 apr 2026, 21:56 UTC

Winsten

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 apr 2026, 21:56 UTC

Winsten

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 apr 2026, 21:55 UTC

Winsten

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 apr 2026, 21:54 UTC

Winsten

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 apr 2026, 21:54 UTC

Winsten

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 apr 2026, 21:53 UTC

Winsten

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 apr 2026, 21:49 UTC

Winsten

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 apr 2026, 21:49 UTC

Winsten

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

12.36% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  12.36%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

186 / 347 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat